The Biotechnology & Pharmaceuticals company released Revenue of $12.5 millions, in the October to December 31 2022

SRZN revealed $12.5 millions, in Revenue in the most recent fiscal period.

Surrozen Inc Competitors, Market Share

Surrozen Inc advance Rates, Profitability, PE

Concentrating on the fourth quarter of 2022 the Communications Services company reached zero gain at $0.00 per share, relative to the earnings of $0.32 per share a year ago financial reporting period, In the prior financial reporting period the Ast Spacemobile Inc realized $-0.18 per share.

Ast Spacemobile Inc Competitors, Market Share

Ast Spacemobile Inc Income Statement, Balance sheets, Cash Flow Statement

Among many entities, the Talaris Therapeutics Inc disclosed also its fourth quarter of 2022 numbers

As the earnings cycle of fiscal October to December 31 2022 period goes on, countless entities have announced the respective earnings. Some of them, have been many constituents of the Biotechnology & Pharmaceuticals sector. And today, Talaris Therapeutics Inc disclosed operating loss of $-19.825 millions, for the most recent fiscal period.

Talaris Therapeutics Inc Customers

Talaris Therapeutics Inc growth Rates, Profitability, PE

Vanishing Deficit at the Inhibikase Therapeutics Inc over the fiscal fourth quarter of 2022

For the fiscal fourth quarter of 2022 IKT decreased a loss per share of $-0.17 per share compare to $-0.20 a year prior and Income per Share improved from $-0.18 per share from the preceding reporting season.

Revenues advanced sharply to $0.06 millions from $0.00 millions in the same reporting season a year prior and sequentially Revenue doubled by 771.842 % from $0.01 millions.

Inhibikase Therapeutics Inc Suppliers

Inhibikase Therapeutics Inc improvement Rates, Profitability, PE

In the October to December 31 2022 company reached 0 at $0.00 per share, opposite of $0.00 per share a year ago reporting season, In the prior reporting season Invesco Db G10 Currency Harvest Fund realized $0.00 per share.

Invesco Db G10 Currency Harvest Fund Customers

Invesco Db G10 Currency Harvest Fund Suppliers

Revenues were $5.940523 millions at the Galaxy Gaming Inc amid the financial interval closing December 31 2022

GLXZ announced declining eps on increasing revenue in the financial interval closing December 31 2022, where Revenue grew by 4.764 % to $5.94 millions in comparison to $5.67 millions on a year-over-year basis, while reached balanced books to $0.00 per share, income per share was $0.02 in the financial span ending December 31 2021.

Galaxy Gaming Inc Suppliers

Galaxy Gaming Inc Suppliers

The Major Pharmaceutical Preparations company added good story for the shareholders, displaying a significant improvement in Dec 31 2022 report with operating loss of $-7.346 millions

Following the bellwethers in the Major Pharmaceutical Preparations sector, some overlooked businesses are coming in with the results. Calithera Biosciences Inc told it has reported operating loss of $-7.346 millions, for the fourth quarter of 2022.

Calithera Biosciences Inc stock quotes, charts, profile

Calithera Biosciences Inc Income Statement, Balance sheets, Cash Flow Statement

Revenues soared and losess have been cut, at VDI in the financial span closing Dec 31 2022

Respectable Revenue elevation in the financial span ending December 31 2022, by 52.984 % to $76.19 millions fueled to cut losses to $-1.33 per share, from $-1.79 in similar the financial reporting period a year ago.

Vantage Drilling International Suppliers

Vantage Drilling International elevation Rates, Profitability, PE

Surrozen Inc reported Revenue of $12.5 millions, in the most recent fiscal period

the Biotechnology & Pharmaceuticals company revealed $12.5 millions, in Revenue in the financial period closing December 31 2022.

Surrozen Inc Competitors, Market Share

Surrozen Inc rise Rates, Profitability, PE

Shifting our regard to the financial three months closing Dec 31 2022 ASTS reached 0 at $0.00 per share, relative to the earnings of $0.32 per share a year ago quarter, In the previous quarter ASTS realized $-0.18 per share.

Ast Spacemobile Inc Customers

Ast Spacemobile Inc Income Statement, Balance sheets, Cash Flow Statement

Working outlays were growing at the TALS in the fiscal fourth quarter of 2022

The Biotechnology & Pharmaceuticals industry reporters start to digest the fourth quarter of 2022 earnings. Today they observe operating loss of $-19.825 millions, from the Talaris Therapeutics Inc , as it hasn't specified any revenue so far, for the own October to December 31 2022 reporting period.

Talaris Therapeutics Inc stock quotes, charts, profile

Talaris Therapeutics Inc Revenue advance Rates

A remarkable result by Inhibikase Therapeutics Inc in the financial time-frame ending December 31 2022

For the fourth quarter of 2022 Inhibikase Therapeutics Inc decreased a loss per share of $-0.17 per share compare to $-0.20 a year ago and Income per Share improved from $-0.18 per share from the previous reporting season.

Revenues surged sharply to $0.06 millions from $0.00 millions in the comparable reporting season a year ago and sequentially Revenue doubled by 771.842 % from $0.01 millions.

Inhibikase Therapeutics Inc Suppliers

Inhibikase Therapeutics Inc Suppliers

A Blowout effort, by SCYX in the financial interval ending December 31 2022

For the most recent fiscal period SCYX decreased a loss per share of $-0.22 per share compare to $-1.08 a year before and earnings per share improved from $-0.62 per share from the preceding reporting season.

Revenues increased sharply by 155.276 % to $1.52 millions from $0.60 millions in the comparable reporting season a year before and sequentially Revenue decreased by -2.119 % from $1.56 millions.

Scynexis Inc Customers

Scynexis Inc Revenue growth Rates